A Phase II, Global, Randomized Study to Evaluate the Efficacy and Safety of Danirixin (GSK1325756) Co-administered With a Standard-of-care Antiviral (Oseltamivir), in the Treatment of Adults Hospitalized With Influenza

Trial Profile

A Phase II, Global, Randomized Study to Evaluate the Efficacy and Safety of Danirixin (GSK1325756) Co-administered With a Standard-of-care Antiviral (Oseltamivir), in the Treatment of Adults Hospitalized With Influenza

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Danirixin (Primary) ; Oseltamivir (Primary)
  • Indications Influenza virus infections
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 Aug 2017 Status changed from recruiting to discontinued due to lack of enrollment.
    • 03 Feb 2017 Planned End Date changed from 1 May 2019 to 1 Jun 2019.
    • 03 Feb 2017 Planned primary completion date changed from 1 May 2019 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top